Short Interest in Raia Drogasil S.A. (OTCMKTS:RADLY) Decreases By 82.3%

Raia Drogasil S.A. (OTCMKTS:RADLYGet Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 3,087 shares, a decrease of 82.3% from the August 15th total of 17,431 shares. Based on an average daily trading volume, of 24,723 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Raia Drogasil Stock Up 0.5%

Shares of RADLY stock opened at $3.81 on Friday. The stock’s fifty day simple moving average is $3.66 and its 200 day simple moving average is $4.01. Raia Drogasil has a one year low of $3.08 and a one year high of $5.34.

Raia Drogasil (OTCMKTS:RADLYGet Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. The company had revenue of $2.17 billion for the quarter, compared to analyst estimates of $2.32 billion. Equities research analysts expect that Raia Drogasil will post 0.17 EPS for the current fiscal year.

Raia Drogasil Company Profile

(Get Free Report)

Raia Drogasil, now operating under the brand name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of pharmacies that sells prescription and over-the-counter medicines, personal-care products, cosmetics, health and wellness items, and convenience products.

The company also provides digital shopping and delivery services through its online channels, supporting customers with medication and health-related purchases. Its operations combine physical stores with e-commerce and other healthcare-related services, serving consumers throughout Brazil.

RD Saúde was formed in 2011 through the merger of Drogasil and Droga Raia, two pharmacy chains with roots dating back to the early twentieth century.

Further Reading

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.